Clearline Capital LP Biomarin Pharmaceutical Inc Transaction History

Clearline Capital LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$54.08 - $68.32 $7.84 Million - $9.9 Million	-144,928 Reduced 51.57%	136,125 $7.48 Million
Q1 2025 May 15, 2025	SELL	$61.25 - $72.83 $5.91 Million - $7.02 Million	-96,429 Reduced 25.55%	281,053 $19.9 Million
Q4 2024 Feb 14, 2025	BUY	$61.93 - $70.49 $3.57 Million - $4.07 Million	57,710 Added 18.05%	377,482 $24.8 Million
Q3 2024 Nov 14, 2024	BUY	$69.02 - $93.84 $22.1 Million - $30 Million	319,772 New	319,772 $22.5 Million

666

182M

1.48M

957K

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $10.2B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Clearline Capital LP, based on Form 13F filings with the SEC.

Stay updated on Clearline Capital LP with notifications on news.